311 related articles for article (PubMed ID: 31203497)
41. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
[TBL] [Abstract][Full Text] [Related]
42. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.
Shimon I; Cohen O; Lubetsky A; Olchovsky D
Thyroid; 2002 Sep; 12(9):823-7. PubMed ID: 12481949
[TBL] [Abstract][Full Text] [Related]
43. Levothyroxine replacement therapy after thyroid surgery.
Verhaert N; Vander Poorten V; Delaere P; Bex M; Debruyne F
B-ENT; 2006; 2(3):129-33. PubMed ID: 17067083
[TBL] [Abstract][Full Text] [Related]
44. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
45. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
46. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis.
Mosaferi T; Tsai K; Sovich S; Wilhalme H; Kathuria-Prakash N; Praw SS; Drakaki A; Angell TE; Lechner MG
Thyroid; 2022 May; 32(5):496-504. PubMed ID: 35199588
[No Abstract] [Full Text] [Related]
47. Levothyroxine Therapy in Thyrodectomized Patients.
Miccoli P; Materazzi G; Rossi L
Front Endocrinol (Lausanne); 2020; 11():626268. PubMed ID: 33584551
[TBL] [Abstract][Full Text] [Related]
48. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
49. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
Serhal DI; Nasrallah MP; Arafah BM
J Clin Endocrinol Metab; 2004 Jul; 89(7):3285-9. PubMed ID: 15240604
[TBL] [Abstract][Full Text] [Related]
50. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients.
Gullo D; Latina A; Frasca F; Le Moli R; Pellegriti G; Vigneri R
PLoS One; 2011; 6(8):e22552. PubMed ID: 21829633
[TBL] [Abstract][Full Text] [Related]
51. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal.
Lin SY; Huang SC; Sheu WH
Metabolism; 2010 Feb; 59(2):195-9. PubMed ID: 19765779
[TBL] [Abstract][Full Text] [Related]
52. [Can the thyrotropin (TSH) suppressive dose of L-thyroxine (T4) be individually predicted in athyroid patients?].
Kainz H; Weissel M
Acta Med Austriaca; 1990; 17(2-3):50-4. PubMed ID: 2120901
[TBL] [Abstract][Full Text] [Related]
53. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
54. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
55. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
57. Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial.
Marina M; Maglietta G; De Filpo G; Aloe R; Gnocchi C; Iezzi E; Caminiti C; Ceresini G
Endocrine; 2022 Aug; 77(2):340-348. PubMed ID: 35751777
[TBL] [Abstract][Full Text] [Related]
58. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.
Ito M; Miyauchi A; Morita S; Kudo T; Nishihara E; Kihara M; Takamura Y; Ito Y; Kobayashi K; Miya A; Kubota S; Amino N
Eur J Endocrinol; 2012 Sep; 167(3):373-8. PubMed ID: 22711760
[TBL] [Abstract][Full Text] [Related]
59. Levothyroxine suppressive therapy in differentiated thyroid cancer treatment.
Drugda J; Čáp J; Kosák M; Gabalec F
Vnitr Lek; 2023; 69(2):128-131. PubMed ID: 37072271
[TBL] [Abstract][Full Text] [Related]
60. Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer.
Liu C; Lv H; Li Q; Fu S; Tan J; Wang C; Wang X; Ma Y
Medicine (Baltimore); 2020 Jul; 99(28):e21190. PubMed ID: 32664162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
